Indima ye-Cannabinoids e-Cancer Care
I-cannabis sativa , eyaziwa kakhulu ngokuthi isitshalo se-marijuana, inomlando omude wemithi. Eqinisweni, kukhona ubufakazi obubhaliwe bokusebenzisa ukwelashwa kwe-cannabis eChina okuthandana eminyakeni engaphezu kwengu-5 000 edlule. Kunconywe ngezifo ezihlukahlukene ezivela kuhudo kanye nezidumbu ezibangelwa isisindo sokugaya isicathulo nesifuba esifubeni, futhi sisetshenziswe njengesifo se-aphrodisiac, ukuhlenga ubuhlungu, nokuxilonga.
Njengoba ulwazi lwethu lomzimba wesintu nesifo lukhula, kanjalo nokuqonda kwethu kule mithi yasendulo. Iyiphi indima i-cannabis edlalwa ekwelapheni ukwelashwa kwelanga lesimanje noma i-lymphoma?
Yini Okungeyona Intsha Yokudla?
Isitshalo se- Cannabis sativa sikhiqiza izinhlobo ezingaphezu kuka-70 zamakhemikhali ezibizwa ngokuthi i-cannabinoids. Nakuba cishe ama-60 kulawa ma-cannabinoids ayasebenza futhi engenamthelela omncane noma awunamthelela emisebenzini yobuchopho bethu, amakhemikhali asele angaba namandla kakhulu futhi angasetshenziswa ngokwemithi ukuphatha izimpawu eziningi.
Okubaluleke kunazo zonke zalezi zinhlobo ze-cannabinoids yi- tetrahydrocannabinol (i-THC) , i-agent esebenzayo emanzini. Ukutholakala kwe-THC ngawo-1960 kuholela ekuthuthukiseni imithi, i-dronabinol (i-Marinol), i-nabilone (i-Cesamet), i-Sativex, i-Levonantradol, ne-Synhexyl ezisekelwe ezinhlobonhlobo zokwenza izinto ze-THC.
I-Cannabinoids isebenza kanjani?
Odokotela babenquma ukuthi bangasebenzisa kanjani izidakamizwa ngaphambi kokuba bazi kahle ukuthi basebenze kanjani.
Kusukela ngaleso sikhathi, abacwaningi bathole ama-receptor amabili emizimbeni yethu lapho isenzo se-cannabinoids sisebenza khona. Ibizwa ngokuthi i-cannabinoid receptor 1 (CB1) ne-receptor 2 ye-cannabinoid (CB2).
I-CB1 iyinhlangano ye-receptor ekhona ikakhulukazi ohlelweni lwethu lwezinzwa oluyinhloko ekwenzeni isisulu, ukuhlanza nokukhathazeka, futhi yilo elichaphazelekayo nge-cannabis ne-THC.
I-CB2 itholakala kwezinye izicubu zomzimba futhi idlala indima emasimini ethu omzimba .
I-cannabinoids ivuselela lezi zitholampilo, ekugcineni eziholela ekusizeni izibonakaliso.
Yini Engayenza Ngayo Amagciwane?
Njengamanje, izidakamizwa zivunyelwe ukusetshenziswa kweziguli zomdlavuza ezinezinyosi kanye nokuhlanza ezingaphenduli ukwelashwa okujwayelekile , kanye nokugqugquzela ukudla kweziguli ezine-AIDS / i-HIV. Ucwaningo lwezokwelapha luye lwabonisa ukuthi ukwelashwa okungenawo umuthi kungasebenza ngempumelelo ukuphatha inani lezimpawu zesiguli somdlavuza:
- Ukucindezeleka
- Ukukhathazeka
- Ubuhlungu
- Ukulahlekelwa kwesisindo
- Ukulala okubi
Ngaphezu kwalokho, ucwaningo luyaqhubeka ukuthola ukuthi imishanguzo ethinta i-CB2 (immunity) receptors ingase ibulale amaseli omdlavuza.
Kubalulekile ukuqaphela ukuthi ukwelashwa okungenayo i-cannabinoid akusebenzi kuwo wonke umuntu, nokuthi ngezinye izikhathi imiphumela emibi ingaphezu kwenzuzo yesidakamizwa. Uma ubhekene nesicanucanu nokuhlanza okungakwazi ukulawulwa, noma ucabanga ukuthi ungazuza emithwaleni yokudla, ungakhuluma nodokotela wakho wezempilo.
Yimiphi imiphumela emibi engayilindela?
Njenganoma imiphi imithi, i-cannabinoids ingabangela imiphumela eminye emibi:
- Ukulala
- Ukudideka
- Umfutho wegazi ophansi
- Umlomo omile
Ezinye iziguli ezithatha i-dronabinol zingase zibe "phezulu" okufana nokuzwa okuhambisana nokubhema inambuzane.
Imiphumela emibi ye-cannabinoids ngokuvamile ihlotshaniswa nokulinganisa okuphezulu futhi ingancipha njengoba uqhubeka ukuyithatha.
Ama-Cannabinoids athathwa kanjani?
Iningi lama-cannabinoids athathwa ngomlomo ngephilisi noma ifomu le-capsule. Isenzo sale mithi singathatha isikhashana ukunikeza usizo, ngakho-ke uma uthatha le mithi ukuze ukhululeke ubuhlungu noma isicanucanu, uzofuna ukuhlala ohlelweni olujwayelekile futhi ungalindeli ukuthi izimpawu zakho ziphumelele ngaphambi kokuthatha it.
I-Sativex, inhlanganisela engu-50/50 ye-THC kanye nesinye isifo se-cannabidiol esabizwa i-cannabidiol, i-liquid esetshenziselwa emlonyeni wakho noma ngaphakathi kwesigama sakho.
Ukuqala kokusebenza kwe-Sativex kuyashesha kunamanye ama-cannabinoids.
Kuthiwani Ngamakhojuana?
Uma imithi yokwelashwa yomshoshaphansi idalwa ebhodini, yenziwe ukuhlangabezana neziqondiso eziqinile kakhulu zomhlaba jikelele. Lezi zidingo zisiza ukuqinisekisa ukuthi umkhiqizo wokuphela uphephile futhi usebenza kahle. Kuye ngokuthi izitshalo ze-cannabis sezikhulile kanjani nokuthi zingakanani, i-marijuana ingashintsha ngokuphawulekayo kusuka ku-batch ukuya ku-batch futhi ingeke ilandele noma yimiphi imihlahlandlela yokuphepha. Ngaphezu kwanoma yikuphi ukukhathazeka lokhu okungase kuphakanyiswe nokuthi umkhiqizo usebenza kahle kangakanani, kungase kube nanoma iyiphi inombolo yokungcola okukhona okungabangela imiphumela emibi noma ukutheleleka uma kuphawulwa.
Ngaphandle kokungekho emthethweni ezindaweni eziningi, ukubhema inambuzane kungase kuholele ekucaseni amaphaphu, futhi, ngokusho kocwaningo oluthile, kungabangela umdlavuza .
Iyifinyelela phezulu
Nakuba imbongi yezokwelapha iye yathandwa emaphephandabeni eminyakeni embalwa edlule, i-cannabis sativa isetshenziswe ekunakekeleni isiguli iminyaka eyizinkulungwane. Njengoba sifunda kabanzi mayelana nezinzuzo zamanye amakhemikhali aqukethwe ku-cannabis, ososayensi balwela ukuhlukanisa nokuhlanza la makhemikhali ukuze kusetshenziswe ngokuphephile.
Imithombo
Guy, G., Stott, C. "Ukuthuthukiswa kwe-Sativex- imithi yokwelashwa engokwemvelo" e-Mechoulam, R. (ed) (2005) I- Cannabinoids njengeTherapeutics Birkhauser Verlag: Basel, Switzerland. (iphe. 231- 263).
UHanus, L., Mechoulam, R. "I-chemistry ye-Cannabinoid: i-Overview" eMechoulam, R. (ed) (2005) I- Cannabinoids njengeTherapeutics uBirkhauser Verlag: iBasel, Switzerland (pp. 23- 46).
U-Musty, R. "I-Cannabinoids nokukhathazeka" eMechoulam, R. (ed) (2005) I- Cannabinoids njengeTherapeutics uBirkhauser Verlag: Basel, Switzerland. (amakhasi 141- 147).
I-Petrocellis, L., Bifulco, M., Ligresti, A., Di Marzo, V. "Ukusetshenziswa okungenzeka kwamannabimimetics ekwelapheni umdlavuza" eMechoulam, R. (ed) (2005) I- Cannabinoids njengeTherapeutics uBirkhauser Verlag: iBasel, ESwitzerland. (amakhasi 165- 181).